A Phase II/III Study to Evaluate the Efficacy and Safety of BAT4406F Injection in Patients with Neuromyelitis Optica Lineage Disease
Latest Information Update: 09 Jul 2025
At a glance
- Drugs BAT 4406F (Primary)
- Indications Neuromyelitis optica
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Bio-Thera Solutions
Most Recent Events
- 02 Jul 2025 Status changed from recruiting to discontinued, according to a Bio-Thera Solutions media release.
- 02 Jul 2025 According to a Bio-Thera Solutions media release, the Independent Data Monitoring Committee (IDMC) has recommended early study termination for the pivotal Phase II/III trial of BAT4406F in neuromyelitis optica spectrum disorder (NMOSD) based on positive interim analysis results. The company has decided to close patient enrollment ahead of schedule.
- 26 Sep 2023 New trial record